Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
Open Access
- 8 April 2014
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (15) , 3651-3665
Abstract
Background and Purpose: The glucagon‐like peptide 1 (GLP‐1) receptor performs an important role in glycaemic control, stimulating the release of insulin. It is an attractive target for treating type 2 diabetes. Recently, several reports of adverse side effects following prolonged use of GLP‐1 receptor therapies have emerged: most likely due to an incomplete understanding of signalling complexities.Experimental Approach: We describe the expression of the GLP‐1 receptor in a panel of modified yeast strains that couple receptor activation to cell growth via single Gα/yeast chimeras. This assay enables the study of individual ligand–receptor G protein coupling preferences and the quantification of the effect of GLP‐1 receptor ligands on G protein selectivity.Key Results: The GLP‐1 receptor functionally coupled to the chimeras representing the human Gαs, Gαi and Gαq subunits. Calculation of the dissociation constant for a receptor antagonist, exendin‐3 revealed no significant difference between the two systems. We obtained previously unobserved differences in G protein signalling bias for clinically relevant therapeutic agents, liraglutide and exenatide; the latter displaying significant bias for the Gαi pathway. We extended the use of the system to investigate small‐molecule allosteric compounds and the closely related glucagon receptor.Conclusions and Implications: These results provide a better understanding of the molecular events involved in GLP‐1 receptor pleiotropic signalling and establish the yeast platform as a robust tool to screen for more selective, efficacious compounds acting at this important class of receptors in the future.Keywords
Funding Information
- University of Warwick (RD13301)
- Biotechnology and Biological Sciences Research Council (BB/G01227X/1)
- University of Warwick (GMRH0508STF)
- Birmingham Science City Research Alliance
This publication has 51 references indexed in Scilit:
- Loss of constitutive activity is correlated with increased thermostability of the human adenosineA2AreceptorBritish Journal of Pharmacology, 2013
- A network meta‐analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placeboDiabetes, Obesity and Metabolism, 2012
- Quantifying Ligand Bias at Seven-Transmembrane ReceptorsMolecular Pharmacology, 2011
- Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human IsletsDiabetes, 2010
- Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug ScreeningMolecular Pharmacology, 2010
- Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Determination of Adenosine A1 Receptor Agonist and Antagonist Pharmacology Using Saccharomyces cerevisiae: Implications for Ligand Screening and Functional SelectivityThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Small-molecule agonists for the glucagon-like peptide 1 receptorProceedings of the National Academy of Sciences, 2007